Table 1 Characteristics of the whole study population
Variable | Whole sample (n = 647) |
|---|---|
Age (years) | 77.5 ± 0.8 |
Urine albumin creatinine ratio (mg/mmol) | 4.6 ± 19.4 |
Serum cystatin C (mg/L) | 1.09 ± 0.28 |
eGFR* (ml/min/1.73 m2) | 73.6 ± 17.4 |
Fasting plasma glucose (mmol/L) | 5.9 ± 1.3 |
Systolic blood pressure (mmHg) | 150.9 ± 20.7 |
Diastolic blood pressure (mmHg) | 81.3 ± 9.7 |
Body mass index (kg/m2) | 26.3 ± 3.5 |
Serum triglyceride (mmol/L) | 1.4 ± 0.6 |
HDL cholesterol (mmol/L) | 1.3 ± 0.3 |
LDL cholesterol (mmol/L) | 3.5 ± 0.9 |
Urine 15-keto-dihydro-PGF2α (nmol/mmol) | 0.32 ± 0.18 |
Serum interleukin-6 (ng/L) | 3.9 ± 2.7 |
Serum amyloid A protein (mg/L) | 11.3 ± 43.6 |
high sensitivity C-reactive protein (mg/L) | 3.8 ± 6.8 |
Urine F2-isoprostane (nmol/mmol) | 0.20 ± 0.10 |
Diabetes mellitus – n (%) | 91 (14.1) |
Smoking – n (%) | 45 (7.0) |
Dyslipidemia – n (%) | 226 (34.9) |
Lipid lowering treatment – n (%) | 119 (18.4) |
Cardiovascular disease – n (%) | 175 (27.1) |
Hypertension – n (%) | 292 (45.1) |
Antihypertensive treatment – n (%) | 272 (42.0) |
ACE-inhibitor – n (%) | 109 (16.9) |
ASA medicine – n (%) | 193 (29.8) |
Corticosteroid treatment – n (%) | 26 (4.0) |
Non-steroidal anti-inflammatory drugs – n (%) | 35 (5.4) |